Mitogen-activated protein kinase cascade in human normal and tumoral parathyroid cells

被引:77
作者
Corbetta, S [1 ]
Lania, A [1 ]
Filopanti, M [1 ]
Vicentini, L [1 ]
Ballaré, E [1 ]
Spada, A [1 ]
机构
[1] Osped Maggiore, IRCCS, Inst Endocrine Sci, I-20122 Milan, Italy
关键词
D O I
10.1210/jc.87.5.2201
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The calcium-sensing receptor (CaR) activation has recently been shown to modulate the ERK1 and ERK2 cascade in different cell lines. The present study investigated this pathway in human normal and tumoral parathyroid cells. In cells from normal parathyroids and almost all hyperplasia increasing extracellular calcium concentrations (Ca-0(2+)) induced a Significant activation of ERK1 and -2, the percent stimulation over basal activity (at 0.5 mM Ca-0(2+)) being 545 +/- 140 and 800 +/- 205 in normal cells and 290 +/- 71 and 350 +/- 73 in hyperplasia at 1 and 2 mM Ca2+, respectively. This effect was mediated by CaR because it was mimicked by the receptor agonist gadolinium. and neomycin. Basal and Ca2+-stimulated ERK1 and -2 activity was nearly abolished by the PKC inhibitor calphostin C, and PKA changes did not affect ERK1 and -2 activity. PI3K blockade by wortmannin, known to prevent G protein betagamma subunit effect on ERK1 and -2, induced a 30% reduction of the Ca2+-stimulated ERK1 and -2 activity. Adenomatous cells showed high PKC-dependent ERK1 and -2 activity in resting conditions that was unresponsive to high Ca2+. A role of MAPK on PTH secretion was suggested by the finding that PD98059, a specific MEK inhibitor, abolished the inhibitory effect of 1.5 mM Ca2+ on PTH release from normal parathyroid cells. In conclusion, these data first demonstrate that CaR activation, through the PKC pathway and, to a lesser extent, PI3K, increases ERK1 and -2 activity in normal parathyroid cells and this cascade seems to be involved in the modulation of PTH secretion by Ca-0(2+). Interestingly, this signaling pathway is disrupted in parathyroid tumors.
引用
收藏
页码:2201 / 2205
页数:5
相关论文
共 30 条
[1]   Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment [J].
Ballarè, E ;
Persani, L ;
Lania, AG ;
Filopanti, M ;
Giammona, E ;
Corbetta, S ;
Mantovani, S ;
Arosio, M ;
Beck-Peccoz, P ;
Faglia, G ;
Spada, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (08) :3809-3814
[2]   SENSING OF EXTRACELLULAR CA2+ BY PARATHYROID AND KIDNEY-CELLS - CLONING AND CHARACTERIZATION OF AN EXTRACELLULAR CA2+-SENSING RECEPTOR [J].
BROWN, EM ;
POLLAK, M ;
HEBERT, SC .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 25 (03) :506-513
[3]   The extracellular calcium-sensing receptor: Its role in health and disease [J].
Brown, EM ;
Pollak, M ;
Hebert, SC .
ANNUAL REVIEW OF MEDICINE, 1998, 49 :15-29
[4]   Coupling of calcium receptors to inositol phosphate and cyclic AMP generation in mammalian cells and Xenopus laevis oocytes and immunodetection of receptor protein by region-specific antipeptide antisera [J].
Chang, WH ;
Pratt, S ;
Chen, TH ;
Nemeth, E ;
Huang, ZM ;
Shoback, D .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (04) :570-580
[5]   The calcium-sensing receptor: A window into the physiology and pathophysiology of mineral ion metabolism [J].
Chattopadhyay, N ;
Mithal, A ;
Brown, EM .
ENDOCRINE REVIEWS, 1996, 17 (04) :289-307
[6]   Cellular "sensing" of extracellular calcium (Ca2+o):: emerging roles in regulating diverse physiological functions [J].
Chattopadhyay, N ;
Brown, EM .
CELLULAR SIGNALLING, 2000, 12 (06) :361-366
[7]   MAP kinase pathways [J].
Cobb, MH .
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 1999, 71 (3-4) :479-500
[8]  
Coffer PJ, 1998, BIOCHEM J, V329, P121
[9]   Regulation of mitogen-activated protein kinase phosphatase-1 expression by extracellular signal-related kinase-dependent and Ca2+-dependent signal pathways in rat-1 cells [J].
Cook, SJ ;
Beltman, J ;
Cadwallader, KA ;
McMahon, M ;
McCormick, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (20) :13309-13319
[10]   Calcium-sensing receptor expression and signalling in human parathyroid adenomas and primary hyperplasia [J].
Corbetta, S ;
Mantovani, G ;
Lania, A ;
Borgato, S ;
Vicentini, L ;
Beretta, E ;
Faglia, G ;
Di Blasio, AM ;
Spada, A .
CLINICAL ENDOCRINOLOGY, 2000, 52 (03) :339-348